Press Release.
Amsterdam – Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT) announces today that it has successfully raised € 14.3 m in gross proceeds through a private placement of new shares with institutional investors, other qualifying investors who subscribed forat least € 50,000 per investor in various jurisdictions and the members of the Board of Management (the “Private Placement”). Pursuant to the Private Placement AMT will issue 8,435,294 new ordinary shares with a nominal value of € 0.04 each for an offer price of € 1.70 per share.
The net proceeds of the Private Placement will increase AMT’s financial flexibility and will be used to fund Glybera® through its regulatory and commercial development and to continue the development of the hemophilia and other pipeline programs.
The payment and delivery of the new shares is expected to take place on October 11, 2010, at which date the new shares are also expected to be admitted to listing on NYSE Euronext in Amsterdam.
Immediately after the closing of the Private Placement, AMT’s issued and outstanding share capital will amount to 23,504,022 ordinary shares.
Pricing Statement
The prospectus that was prepared in relation to the admission to listing and trading of the shares was made generally available on 5 October 2010. Today, AMT deposited a pricing statement with the Authority of the Financial Markets (Stichting Autoriteit Financiële Markten) mentioning amongst others the number of new shares to be issued and the issue price of the new shares. The prospectus and the pricing statement are available via AMT’s website.
Kempen & Co and Petercam Nederland N.V. have acted as joint global coordinators and bookrunners for the Private Placement.
About Amsterdam Molecular Therapeutics
AMT is a leader in the development of human gene based therapies. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. This proprietary platform can be applied to a large number of rare (orphan) diseases that are caused by one faulty gene. Currently, AMT has a product pipeline with several AAV-based gene therapy products in LPLD, Hemophilia B, Duchenne Muscular Dystrophy, Acute Intermittent Porphyria, and Parkinson’s Disease at different stages of research or development. AMT was founded in 1998 and is based in Amsterdam.
Not for release, publication or distribution in whole or in part, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or to US persons. This announcement is not a prospectus and is not an offer for sale of securities in the United States, Canada, South Africa, Australia, Japan or any other jurisdiction.
The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “”Securities Act””), and may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.
In connection with the admission of the shares in the capital of Amsterdam Molecular Therapeutics (AMT) Holding N.V. to listing and trading on NYSE Euronext in Amsterdam a prospectus has been made generally available (the “”Prospectus””). The Prospectus is available at no cost through the website of AMT, and is also available via the website of NYSE Euronext (Dutch residents only) and by sending a request in writing to AMT (P.O. Box 22506, 1100 DA Amsterdam, The Netherlands).
For further enquiries:
Ellen Roest
AMT Communications
Tel : +31 6 2900 6179
e.roest@amtbiopharma.com
Mike Sinclair
Halsin Partners
Tel : +44 20 7318 2955
msinclair@halsin.com
Jörn Aldag
CEO
Tel +31 20 566 7394
j.aldag@amtbiopharma.com
Certain statements in this press release are “forward-looking statements” including those that refer to management’s plans and expectations for future operations, prospects and financial condition. Words such as “strategy,” “expects,” “plans,” “anticipates,” “believes,” “will,” “continues,” “estimates,” “intends,” “projects,”“goals,” “targets” and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT’s business.
AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, reference is made to the Prospectus and AMT’s public announcements made from time to time.
